Skip to main navigation Skip to search Skip to main content

Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer

  • Kyeonghui Kim
  • , Hyemin Kim
  • , Inkyung Shin
  • , Seung Jae Noh
  • , Jeong Yeon Kim
  • , Koung Jin Suh
  • , Yoo Na Kim
  • , Jung Yun Lee
  • , Dae Yeon Cho
  • , Se Hyun Kim
  • , Jee Hyun Kim
  • , Se Hoon Lee
  • , Jung Kyoon Choi
  • Korea Advanced Institute of Science and Technology
  • Ltd
  • Seoul National University
  • Yonsei University

Research output: Contribution to journal › Article › peer-review

Abstract

Genomic hypomethylation has recently been identified as a determinant of therapeutic responses to immune checkpoint blockade (ICB). However, it remains unclear whether this approach can be applied to cell-free DNA (cfDNA) and whether it can address the issue of low tumor purity encountered in tissue-based methylation profiling. In this study, we developed an assay named iMethyl, designed to estimate the genomic hypomethylation status from cfDNA. This was achieved through deep targeted sequencing of young LINE-1 elements with > 400,000 reads per sample. iMethyl was applied to a total of 653 ICB samples encompassing lung cancer (cfDNA n = 167; tissue n = 137; cfDNA early during treatment n = 40), breast cancer (cfDNA n = 91; tissue n = 50; PBMC n = 50; cfDNA at progression n = 44), and ovarian cancer (tissue n = 74). iMethyl-liquid predicted ICB responses accurately regardless of the tumor purity of tissue samples. iMethyl-liquid was also able to monitor therapeutic responses early during treatment (3 or 6 weeks after initiation of ICB) and detect progressive hypomethylation accompanying tumor progression. iMethyl-tissue had better predictive power than tumor mutation burden and PD-L1 expression. In conclusion, our iMethyl-liquid method allows for reliable noninvasive prediction, early evaluation, and monitoring of clinical responses to ICB therapy.

Original languageEnglish
Article number22482
JournalScientific Reports
Volume13
Issue number1
DOIs
StatePublished - Dec 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer'. Together they form a unique fingerprint.

Cite this